TY - JOUR
T1 - Alternatives for Allergens in the 2018 American Contact Dermatitis Society Core Series
T2 - Report by the American Contact Alternatives Group
AU - Scheman, Andrew
AU - Hylwa-Deufel, Sara
AU - Jacob, Sharon E.
AU - Katta, Rajani
AU - Nedorost, Susan
AU - Warshaw, Erin
AU - Eifrid, Kathryn
AU - Geiser, Andrew J.
AU - Mcgaughey, Lauren
AU - Scheman, Nicole
AU - Kimyon, Rebecca
AU - Rundle, Chandler
AU - Shaver, Rob
N1 - Publisher Copyright:
© 2019 Lippincott Williams & Wilkins.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - The most successful treatment for contact allergy is allergen avoidance. Patient improvement ultimately relies on identification of safe alternative products, which can be used by the patient. "Safe" personal care product options can typically be found using ingredient database programs. Avoidance of allergens in other products (ie, shoes, clothing, dental care, etc) is often challenging. In this article, the American Contact Alternatives Group discusses how to find specific safe alternatives for the 80 allergens on the American Contact Dermatitis Society core allergen series (Dermatitis. 2017;28:141-143). The alternatives listed in this article are accurate as of the date of publication; however, the availability of these alternatives may change in the future (disclaimer).
AB - The most successful treatment for contact allergy is allergen avoidance. Patient improvement ultimately relies on identification of safe alternative products, which can be used by the patient. "Safe" personal care product options can typically be found using ingredient database programs. Avoidance of allergens in other products (ie, shoes, clothing, dental care, etc) is often challenging. In this article, the American Contact Alternatives Group discusses how to find specific safe alternatives for the 80 allergens on the American Contact Dermatitis Society core allergen series (Dermatitis. 2017;28:141-143). The alternatives listed in this article are accurate as of the date of publication; however, the availability of these alternatives may change in the future (disclaimer).
UR - http://www.scopus.com/inward/record.url?scp=85063013998&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063013998&partnerID=8YFLogxK
U2 - 10.1097/DER.0000000000000453
DO - 10.1097/DER.0000000000000453
M3 - Article
C2 - 30870231
SN - 1710-3568
VL - 30
SP - 87
EP - 105
JO - Dermatitis
JF - Dermatitis
IS - 2
ER -